Qiagen N.V. Share Price Xetra

Equities

QIA

NL0015001WM6

Biotechnology & Medical Research

Market Closed - Xetra 09:05:19 26/04/2024 pm IST 5-day change 1st Jan Change
38.76 EUR +2.16% Intraday chart for Qiagen N.V. +3.44% -4.58%

Financials

Sales 2024 * 2.01B 1.88B 168B Sales 2025 * 2.14B 2B 179B Capitalization 9.22B 8.61B 769B
Net income 2024 * 398M 372M 33.18B Net income 2025 * 442M 413M 36.85B EV / Sales 2024 * 4.74 x
Net Debt 2024 * 300M 281M 25.04B Net cash position 2025 * 280M 262M 23.36B EV / Sales 2025 * 4.17 x
P/E ratio 2024 *
23.5 x
P/E ratio 2025 *
21 x
Employees 5,361
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.45%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.16%
1 week+3.44%
Current month-2.21%
1 month-2.21%
3 months-8.32%
6 months+9.39%
Current year-4.58%
More quotes
1 week
37.85
Extreme 37.845
39.10
1 month
36.59
Extreme 36.585
39.76
Current year
36.59
Extreme 36.585
43.40
1 year
33.75
Extreme 33.7526
44.81
3 years
33.75
Extreme 33.7526
53.15
5 years
23.24
Extreme 23.2371
53.15
10 years
16.63
Extreme 16.6314
53.15
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 01/15/01
Founder 69 29/96/29
Director of Finance/CFO 56 01/99/01
Members of the board TitleAgeSince
Director/Board Member 74 01/11/01
Founder 69 29/96/29
Chairman 66 26/13/26
More insiders
Date Price Change Volume
26/24/26 38.76 +2.16% 834,392
25/24/25 37.94 -1.65% 1,131,178
24/24/24 38.58 -0.89% 853,570
23/24/23 38.92 +1.26% 750,950
22/24/22 38.44 +2.58% 823,535

Delayed Quote Xetra, April 26, 2024 at 09:05 pm IST

More quotes
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
41.65 USD
Average target price
50.75 USD
Spread / Average Target
+21.86%
Consensus